Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 3/20 | 0.44 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | ERBB3 | P21860 | 6/20 | 0.41 |
| ▸ | MPL | P40238 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 4/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4112001 | 0.87 | L3MBTL1 (0.46) | EGFRL3MBTL1CHEK1JAK2ABL1 | |
| SCHEMBL2174775 | 0.78 | MEN1 (0.68) | EGFRCHEK1ABL1BCRERBB3 | |
| SCHEMBL4108813 | 0.77 | NPC1 (0.56) | EGFRL3MBTL1JAK2ERBB3 | |
| SCHEMBL8798594 | 0.73 | EGFR (0.85) | EGFRL3MBTL1CHEK1 | |
| SCHEMBL4760023 | 0.72 | EGFR (0.60) | EGFRABL1BCRERBB3MPL | |
| SCHEMBL4108856 | 0.72 | CYP1A2 (0.52) | L3MBTL1ABL1BCR | |
| SCHEMBL4103359 | 0.72 | JAK3 (0.50) | EGFRL3MBTL1JAK2ERBB3JAK3 | |
| SCHEMBL4116164 | 0.71 | CYP1A2 (0.54) | EGFRL3MBTL1ERBB3 | |
| SCHEMBL12487942 | 0.71 | JAK2 (0.60) | JAK2ABL1BCRJAK3JAK1 | |
| SCHEMBL4109552 | 0.71 | MPL (0.52) | EGFRERBB3MPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221581-A1 | Methods of treating pain | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | claimed |
| US-20090221581-A1 | Methods of treating pain | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221581-A1 | Methods of treating pain | CDK5, CAMKK2, CDK3 | EGFR 4439/4885L3MBTL1 3236/4885CHEK1 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.